[go: up one dir, main page]

WO2001013928A1 - Procedes de pasteurisation d'une substance immune contenant un facteur anti-inflammatoire et son utilisation - Google Patents

Procedes de pasteurisation d'une substance immune contenant un facteur anti-inflammatoire et son utilisation Download PDF

Info

Publication number
WO2001013928A1
WO2001013928A1 PCT/JP2000/005642 JP0005642W WO0113928A1 WO 2001013928 A1 WO2001013928 A1 WO 2001013928A1 JP 0005642 W JP0005642 W JP 0005642W WO 0113928 A1 WO0113928 A1 WO 0113928A1
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory factor
sterilized
substance
inflammatory
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2000/005642
Other languages
English (en)
Japanese (ja)
Inventor
Naoyuki Kamata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORTHO Corp CO Ltd
Original Assignee
ORTHO Corp CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ORTHO Corp CO Ltd filed Critical ORTHO Corp CO Ltd
Priority to AU67265/00A priority Critical patent/AU6726500A/en
Publication of WO2001013928A1 publication Critical patent/WO2001013928A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to sterilization and sterilization of an anti-inflammatory factor-containing immunological substance.
  • the present invention relates to a method for sterilizing and sterilizing a heat-sensitive anti-inflammatory factor-containing immunological substance without impairing its effect, and to the use of an anti-inflammatory factor-containing immunological substance sterilized and sterilized by the method.
  • Inflammation refers to "a local reaction that, when injured or destroyed, causes both the cause of the injury and destroys, dilutes, or isolates the injured tissue," including “pain, fever, redness, swelling, It is accompanied by signs such as “loss of function” (Roland Medical Encyclopedia).
  • anti-inflammatory drugs are generally given.
  • anti-histamine drugs, steroid and non-steroid anti-inflammatory drugs, anti-inflammatory enzyme agents or immunosuppressive agents are known.
  • each of these anti-inflammatory drugs has a problem of causing side effects and adverse reactions.
  • salicylates one of the most common anti-inflammatory drugs, especially aspirin, are well known, but at high doses can cause central respiratory paralysis and circulatory collapse, epigastric pain, nausea, vomiting and It is thought to cause gastrointestinal bleeding.
  • An anti-inflammatory drug composition derived from milk has been proposed as an anti-inflammatory agent having no such side effects or adverse reactions (Japanese Patent Application Laid-Open No. 18853, JP-A-59-161316), and the isolation of the anti-inflammatory factor and its use as an anti-inflammatory drug have been proposed (Japanese Patent Application Laid-Open No. 2-50 / 1990). 380, Tohoku 8-5 0 2 5 15, Tohoku 8-5 0 2 7 18, Tohoku 1 0-5 0 9 4 2 0).
  • An object of the present invention is to provide a technique for using an anti-inflammatory factor-containing immunological substance including an anti-inflammatory factor derived from milk as a so-called health food.
  • the term "immune substance containing an anti-inflammatory factor” refers to mammals that have become hyperimmune with an adjuvant combination vaccine using attenuated or killed microorganisms, attenuated viruses or inactivated viruses, or toxins.
  • This is an immunological substance obtained by mixing a milk protein fraction and a low molecular weight fraction having a molecular weight of 10,000 or less, separated from whey obtained after defatting and decasein using female milk as a raw material.
  • the milk protein fraction and each fraction of the low molecular weight fraction having a molecular weight of 10,000 or less can be obtained from whey by, for example, separation by chromatography, separation by gel filtration, or separation by ultrafiltration.
  • Tokuhei Hei 2—5 0 3 8 0 2 Tokio Hei 8—5 0 2 5 1 5, Tokio Hei 8—5 0 2 7 1 8, Tokuhyo Hei 10—5 0 9 4 2 0 Etc. can be used.
  • the anti-inflammatory factor-containing immunological substance has an intestinal environment-improving effect on humans and animals, and a concomitant immunity-enhancing effect and an anti-inflammatory effect.
  • the substance can be injected orally or into the body through the anus in the form of a solution, powder, granules or a form added to food or drink.
  • Specific effects include improving the intestinal environment, improving constipation, preventing and treating colon cancer, preventing and treating opportunistic infections, preventing and treating neoplastic diseases, alleviating immunodeficiency, and preventing periodontal disease. Treatment, prevention and treatment of gingivitis, prevention and treatment of ulcer disease, alleviation of rheumatic symptoms, prevention and treatment of asthma.
  • the bovine inflammatory factor-containing immunological substance is It is a useful substance that is effective without side effects.
  • This anti-inflammatory effect can be confirmed, for example, by an air porch method.
  • the principle of the air porch method is as follows. Oral administration of a substance with anti-inflammatory properties, creating an air porch (air cavity) under the skin of the mouse, injecting carrageenan (a source of inflammation), and measuring the number of leukocytes migrating. At this time, if inflammation develops, leukocytes migrate to the affected area and are infiltrated, so the greater the number of leukocytes, the greater the degree of inflammation. Conversely, the stronger the anti-inflammatory effect, the lower the number of leukocytes that migrate and infiltrate.
  • the inflammatory factor-containing immunogenic substance has a disadvantage that it is particularly vulnerable to heat, that is, loses its effect when exposed to high temperatures.
  • a heating method is used to sterilize and sterilize many foods and beverages. Therefore, when trying to use an anti-inflammatory factor-containing immunological substance as a health food, the property of losing its activity by heating is a major obstacle. From this point of view, in using the anti-inflammatory factor-containing immunological substance as a health food, a method of sterilizing and sterilizing without impairing the effect of the anti-inflammatory factor-containing immunological substance is important.
  • An object of the present invention is to provide a method for overcoming the above-mentioned disadvantages of an anti-inflammatory factor-containing immunological substance and sterilizing or sterilizing the substance without impairing the effect of the substance.
  • the present invention further seeks to utilize a sterilized and sterilized anti-inflammatory factor-containing immunological substance as a health food. Disclosure of the invention
  • the invention according to claim 1 is characterized in that the solution of the anti-inflammatory factor-containing immunological substance is heat-treated at a temperature of 55 to 70 ° C. for 30 to 60 minutes. , Sterilization method.
  • Claim 2 The invention provides a method for sterilizing and sterilizing an anti-inflammatory factor-containing immunological substance, which comprises filtering a solution of the anti-inflammatory factor-containing immunological substance through a filter having a pore size of 0.1 to 0.22111.
  • the invention of claim 3 is a substance containing an anti-inflammatory factor-containing immunological substance sterilized by the method of claim 1 or 2.
  • the invention of claim 4 is an ice cream, yogurt, liquid drink, jam, butter, cheese, cream, ice confection to which an anti-inflammatory factor-containing immunological substance sterilized by the method of claim 1 or 2 is added. , Mayonnaise, dressings and other foods and beverages.
  • the anti-inflammatory factor-containing immunological substance is a relatively new substance, the properties of the substance, the method of use, and the like have not yet been sufficiently clarified. It is not yet clear under what conditions sterilization and sterilization methods for anti-inflammatory factor-containing immunological substances should be treated.
  • This invention is the first to clarify the conditions for sterilization and sterilization of anti-inflammatory factor-containing immunological substances.
  • a method of performing heat treatment at 62 ° C for 30 minutes at 4-6650 and for 15 seconds at 75 ° C is described.
  • This sterilization method relates only to milk containing immunoglobulin, not to the anti-inflammatory factor-containing immunological substance of the present invention. Therefore, the method of sterilizing and sterilizing immunological substances containing anti-inflammatory factors is naturally different from the method of sterilizing milk containing immunoglobulin.
  • the anti-inflammatory factor-containing immunological substance is a substance obtained by mixing a milk protein fraction and a low molecular weight fraction having a molecular weight of 10,000 or less, separated from whey obtained after defatting and decasein. Containing no milk fat, lactose, casein, etc. Milk fat, lactose, casein, etc. The effect of heating when not containing is greater than when milk fat, lactose, casein, etc. are contained. Therefore, when lactose, casein, etc. are not contained, it is needless to say that individual sterilization and sterilization methods are required when they are contained.
  • the present invention does not prescribe an anti-inflammatory factor-containing immunological substance as a drug, but is intended for use as a so-called health food, adapted to food and drink.
  • an anti-inflammatory factor-containing immunological substance as a drug
  • the present invention does not prescribe an anti-inflammatory factor-containing immunological substance as a drug, but is intended for use as a so-called health food, adapted to food and drink.
  • the present inventor As a method for disinfecting and sterilizing the anti-inflammatory factor-containing immunological substance without impairing its effect, the present inventor has proposed a disinfection and sterilization method in which the treatment is performed at a specific temperature range, and a filtration method in which filtration is performed using a filter having a small pore size.
  • the present inventors have found that the present invention is suitable, and have completed the present invention.
  • the present invention provides a food or drink obtained by adding an anti-inflammatory factor-containing immunological substance sterilized or sterilized by these methods, and the food or drink is useful as a health food having an anti-inflammatory effect or an immune enhancing effect. It is something.
  • an immune substance containing an anti-inflammatory factor is dissolved in water to obtain an aqueous solution.
  • the concentration of the aqueous solution is 0.
  • This aqueous solution is heat-treated at a temperature of 55 to 70 ° C. for 30 to 60 minutes.
  • This treatment it is possible to sterilize and sterilize the anti-inflammatory factor-containing immunological substance without impairing the anti-inflammatory effect and the immune enhancing effect.
  • Temperature and time depend on each other, but temperature itself is important. The present inventors have found that when the treatment temperature exceeds 70 ° C., the anti-inflammatory effect of the substance is extremely reduced. Ma If the treatment temperature is too low, sterilization and sterilization effects cannot be expected. Therefore, it is necessary to treat at a temperature of at least 55 ° C. To sterilize and sterilize immunological substances containing anti-inflammatory factors, it is necessary to treat them at a temperature in the range of 55 to 70 ° C.
  • the aqueous solution of the anti-inflammatory factor-containing immunological substance sterilized or sterilized in this manner may be used as it is, or in the form of a powder or a concentrated solution by freeze-drying or low-temperature drying treatment, in the form of ice cream, yogurt, liquid drink, It can be added to jams, butters, cheeses, creams, frozen desserts, mayonnaise, dressings, and other foods and beverages.
  • An appropriate amount of a solution or powder of an anti-inflammatory factor-containing immunological substance is added to the raw materials of each of the above-mentioned materials, and finishing is performed according to the standard method of each food and drink.
  • the anti-inflammatory factor-containing immunological substance varies depending on each material, it is generally about 1 to 20% by weight as a solid content, but is not limited thereto. By adding such an amount, an anti-inflammatory effect and an immune-enhancing effect are exhibited. Since each of the above-mentioned materials does not have a treatment to apply a particularly high heat, a sterilized and sterilized aqueous solution can be used effectively.
  • the aqueous solution of the anti-inflammatory factor-containing immunological substance can be sterilized and sterilized by filtration through a filter having a pore size of 0.1 to 0.22 / xm. Bacteria do not pass through this opening filter, and can be sterilized and sterilized by treating with the filter.
  • the filter used here is made of a cellulose mixed membrane or the like. In the filtration operation, an aqueous solution having a concentration of the anti-inflammatory factor-containing immunological substance of 20% or less is subjected to pressurization at a temperature at which the substance is not denatured, for example, at a temperature of 40 ° C. or less.
  • An aqueous solution of an anti-inflammatory factor-containing immune substance sterilized and sterilized in this way.
  • the ice cream, yogurt, liquid drink, jam, butter, cheese, cream, ice dessert, mayone are prepared in the same manner as in the sterilization obtained by heat sterilization, sterilization obtained above, and the sterilized anti-inflammatory factor-containing immune substance aqueous solution.
  • the methods of sterilizing and sterilizing the anti-inflammatory factor-containing immunological substance by heating or using a filter are all treated as aqueous solutions.
  • a solution but not necessarily an aqueous solution.
  • a solvent other than water for example, ethyl alcohol or an aqueous solution of ethyl alcohol can be used.
  • the solution of the immunogenic substance containing the pro-inflammatory factor which has been sterilized or sterilized by heating or filtering, may be added to food or drink as it is, or may be used in the form of a concentrate or powder by freeze-drying or low-temperature drying. It has already been mentioned that it can be used.
  • ice cream Add 10% by weight of an anti-inflammatory factor-containing immunological substance sterilized by a filter to raw materials such as milk, cream, eggs, and seasonings, mix well with a homogenizer, and mix the mixture at 68 ° C. Heat for 30 minutes and sterilize. After cooling the sterilized mixture to 2-5 ° C, it was overrun at -15 ° C and air was entrapped to obtain an ice cream. This ice cream is a health food with anti-inflammatory and immune-enhancing effects.
  • the anti-inflammatory factor-containing immunological substance sterilized by filtration or heat treatment may be added after the ice cream raw material mixture is sterilized.
  • Mayonnaise was heat treated at 68 ° C for 30 minutes and sterilized. It can be obtained by mixing and emulsifying immunogenic substances (15% by weight), salad oil, spices, seasonings, and sterilized egg yolk. Similarly, it can be served as a health food. It goes without saying that an immunological substance containing an anti-inflammatory factor sterilized by filtration can also be used.
  • Strawberries were mixed with an anti-inflammatory factor-containing immunological substance (12% by weight) which had been filtered through a 0.22 im pore size filter and sterilized, and heated to 68 ° C. After concentrating in vacuo at the same temperature, pectin was added and sterilized by heating at 68 for 30 minutes.
  • the anti-inflammatory factor-containing immunological substance (12% by weight) may be added to strawberries simultaneously with pectin. In this way, a strawberry jam containing the fangitis inflammatory factor-containing immunological substance (12% by weight) was obtained. It goes without saying that various fruits can be used instead of strawberries.
  • An anti-inflammatory factor-containing immunological substance (18% by weight) is added to the liquid drink preparation, and the mixture is filtered through a filter having a pore size of 0.22 xm. Obtained. Further, instead of filtration, after addition of the anti-inflammatory factor-containing immunological substance, a heat treatment at a temperature of 68 ° C. for 30 minutes may be performed.
  • the inflammatory factor-containing immunogenic substance is treated at 65 ° C for 30 minutes, sterilized, and cooled to 45-48 ° C.
  • add additives to the milk heat, mix, homogenize, and sterilize at a temperature of 90 to 95 ° C.
  • the milk is cooled to 45-48, and the anti-inflammatory factor-containing immunological substance cooled to 45-48 is added to the milk, mixed, and mixed with Star Yuichi. Fill the mixture into a fermentation container and ferment. Cool to room temperature to form a product.
  • the milk becomes a hard yogurt when the aqueous solution of the stabilizer and the flavor are added to the milk.
  • An anti-inflammatory substance was orally administered, an air pouch (air cavity) was created under the mouse skin, carrageenan (a source of inflammation) was injected, and the number of leukocytes migrating was measured. The following four samples were used for this test.
  • S-100 milk Skim milk powder prepared from cow milk immunized with dead bacteria of 26 pathogenic microorganisms ( ⁇ Cutinize) dissolved in purified water to a concentration of 60% by weight.
  • WPI + solution S—100% milk separated from milk
  • the MU F also ultrafiltered and separated from the S—100 milk in the Park fraction
  • MDF solution An anti-inflammatory fraction obtained by ion-exchange column separation from S-100 milk and dissolved in purified water to a concentration of 0.1% by weight. The operation is as follows.
  • mice such as C 3 H were used.
  • the washed cell-containing solution was centrifuged by a centrifuge.
  • Table 1 shows the measurement results, that is, the number of cells infiltrated into the air porch.
  • the control and commercial milk showed almost the same leukocyte infiltration number, while the S-100 milk, WPI + solution and MUF had a lower leukocyte infiltration number than the control and had an anti-inflammatory effect. I understand.
  • WPI + refers to the anti-inflammatory factor-containing immunological substance of the present invention.
  • the optical density of this sample solution was measured using a microplate reader, and the remaining activity of the anti-inflammatory factor was determined by comparing the optical density with a separately prepared calibration curve. The results are shown in Table 2.
  • the activity remaining ratio is a relative value (%) in which the activity value at room temperature is shown as 100.
  • the residual activity of the immunopotentiating factor sharply decreases, and the treatment temperature of 70 ° C becomes a critical point.
  • the residual ratio of immunopotentiating factor activity is up to 68 ° C Although it is maintained at 80% or more, the activity is almost halved at the treatment temperature of 70 ° C, and almost no activity remains at the treatment temperature of 75 ° C.
  • the number of colonies in the unheated sample on the normal agar medium was 93, but no colony was observed in the heated sample at 65 ° C or higher.
  • the number of colonies in the sample heated at 60 ° C was 4 and 3 at 55 ° C. From this result, it can be seen that sterilization can be achieved by heating at 55 ° C or more, and further, that the number of colonies can be zero, that is, sterilization can be achieved by heating at 65 ° C or more.
  • Example 2 As described above, from the results of Example 2 and Example 3, the activity of the anti-inflammatory factor was maintained. It can be seen that the temperature range where both sterilization and sterilization are compatible is in the range of 55 to 70 ° C. Therefore, in order to sterilize and sterilize without losing the activity of the anti-inflammatory factor, it is preferable to treat at a temperature of 55 ° C to 70 ° C.
  • Example 4 describes a method of sterilizing and sterilizing using a filter.
  • Fuji Photo Film Co., Ltd. product number F M-222 (which has a diameter of 47 mm and a pore size of 0.22 m) was used as a filter, and Shibata Machinery was used as a filtration unit. The one used by Kagaku Kogyo Co., Ltd. was used. 2 g of the anti-inflammatory factor-containing immunological substance was taken and dissolved in water to prepare a total volume of 20 ml. This solution was centrifuged at 1000 G for 10 minutes, and the centrifuged supernatant was collected. This sample solution was subjected to a filtration treatment with a filter unit, which was provided with a filter and sterilized. The filtrate was diluted with sterile PBS (phosphate buffered saline) to prepare 0.8% and 1.2% sample solutions.
  • sterile PBS phosphate buffered saline
  • a PBS solution containing sheep albumin in the kit was used to examine the activity of anti-inflammatory factors using a RID (one-way immunodiffusion method) kit manufactured by The B Inding Site.
  • RID one-way immunodiffusion method
  • Each sample solution was dispensed into a well and incubated at room temperature for 72 hours.
  • the diameter of the settling circle was measured using a caliper. From the data, the equation of the weighing line was obtained, and the data was processed using the equation to calculate the amount of the anti-inflammatory factor in each sample solution. The results are shown in Table 4.
  • Table 4 shows the detected concentration, the activity amount, the residual activity ratio when the untreated sample was set to 100%, and the average value of the residual activity ratio. Each sample showed almost the same value regardless of whether it was filtered or not. The force with which the value of the processed sample is as high as 1%. Within the reproducibility range guaranteed by the kit itself. There is no problem. It was found that the activity of the anti-inflammatory factor by the filtration treatment was not changed by the filtration operation.
  • the number of bacteria was measured in the same manner as in Example 3. That is, 2 g of an anti-inflammatory factor-containing immunological substance was taken and dissolved in water to prepare a total volume of 20 m 1. One colony of Escherichia coli cultured in another medium was added to this solution and mixed. Filtration was performed on 10 ml of this sample solution using a filter unit that was sterilized by installing a filter. 0.1 ml of the filtered sample solution and 0.1 ml of the untreated sample solution were each diluted with sterilized PBS to 10 ml to obtain a sample.
  • Each sterilized instrument was carried into a clean bench and inoculated under the aseptic conditions.
  • Each of the prepared test solutions 1001 was placed on each prepared agar medium, and was uniformly applied with a glass rod. This medium was placed in a 37 ° C incubator and incubated for 24 hours. After 24 hours, the number of generated colonies was determined. Table 5 shows the results of the measurement of the number of generated colonies.
  • the bactericidal and antibacterial anti-inflammatory factor-containing immunological substance obtained by these treatments can be added to various foods and drinks, and is useful as a health food.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention a trait à des procédés de pasteurisation/stérilisation de substances immunes contenant des facteurs anti-inflammatoires et ce, sans porter préjudice aux propriétés anti-inflammatoires et immuno-stimulantes de ces substances, ainsi qu'à l'utilisation qui est faite de ces substances pasteurisées/stérilisées en tant qu'aliments diététiques. Elle porte, notamment, sur des procédés de pasteurisation/stérilisation de substances immunes contenant des facteurs anti-inflammatoires, lesquels procédés consistent à chauffer une solution constituée par ces substances immunes à une température comprise entre 55 et 70°C pendant un laps de temps allant de 30 à 60 minutes ou à la filtrer au moyen d'un filtre dont la taille des pores est comprise entre 0,1 et 0,22 νm. L'invention concerne, de surcroît, des aliments ainsi que des boissons, notamment des crèmes glacées, des yogourts, des boissons, de la confiture, du beurre, du fromage, de la crème, des sorbets, de la mayonnaise, des sauces et analogue, contenant les substances immunes renfermant des facteurs anti-inflammatoires ayant été pasteurisées/stérilisées par le biais des procédés susmentionnés.
PCT/JP2000/005642 1999-08-24 2000-08-23 Procedes de pasteurisation d'une substance immune contenant un facteur anti-inflammatoire et son utilisation Ceased WO2001013928A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU67265/00A AU6726500A (en) 1999-08-24 2000-08-23 Methods of pasteurizing immune substance containing antiinflammatory factor and utilization thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23627699 1999-08-24
JP11/236276 1999-08-24

Publications (1)

Publication Number Publication Date
WO2001013928A1 true WO2001013928A1 (fr) 2001-03-01

Family

ID=16998397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/005642 Ceased WO2001013928A1 (fr) 1999-08-24 2000-08-23 Procedes de pasteurisation d'une substance immune contenant un facteur anti-inflammatoire et son utilisation

Country Status (2)

Country Link
AU (1) AU6726500A (fr)
WO (1) WO2001013928A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007182408A (ja) * 2006-01-10 2007-07-19 Kitasato Gakuen 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006321A1 (fr) * 1989-11-06 1991-05-16 Stolle Research & Development Corporation Utilisation du miel comme vaccin
JPH04283519A (ja) * 1991-03-12 1992-10-08 Eisai Co Ltd 加齢に伴う免疫機能低下を抑制する組成物
JPH04352729A (ja) * 1984-02-07 1992-12-07 Stolle Res & Dev Corp ウシ科動物の抗体を用いた哺乳動物の受動免疫化
US5352462A (en) * 1982-06-03 1994-10-04 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352462A (en) * 1982-06-03 1994-10-04 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
JPH04352729A (ja) * 1984-02-07 1992-12-07 Stolle Res & Dev Corp ウシ科動物の抗体を用いた哺乳動物の受動免疫化
WO1991006321A1 (fr) * 1989-11-06 1991-05-16 Stolle Research & Development Corporation Utilisation du miel comme vaccin
JPH04283519A (ja) * 1991-03-12 1992-10-08 Eisai Co Ltd 加齢に伴う免疫機能低下を抑制する組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007182408A (ja) * 2006-01-10 2007-07-19 Kitasato Gakuen 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物

Also Published As

Publication number Publication date
AU6726500A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
AU771583B2 (en) Bone resorption suppressing agent
GB1573995A (en) Process for the production of a protein concentrate containing immunological factors of lactic origin
WO2006035979A1 (fr) Composition fonctionnelle ou aliment contenant des proteines de lactoserum, anticorps derive du lait ou anticorps
JP5951087B2 (ja) インフルエンザ感染症の予防組成物
JP2001158736A (ja) 骨関節疾患の予防及び改善剤
CA2349980C (fr) Methode de production de fractions contenant une forte concentration de cystatine, une proteine de base du lait, et produits de decomposition connexes
JP2001346519A (ja) 乳塩基性シスタチン高含有画分及びその分解物の製造方法
JP4647750B2 (ja) 乳塩基性シスタチン高含有画分及びその分解物の製造法
KR20030061437A (ko) 항체함유 우유의 제균방법 및 제균처리된 항체함유 우유를함유하는 제품
WO1993012807A1 (fr) Agent de consolidation des os, et aliment et boisson contenant ledit agent
AU784087B2 (en) Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof
TWI620505B (zh) 發酵乳類及其製造方法
JP4688457B2 (ja) 免疫増強組成物
US7547770B2 (en) Colostral fractionation process
WO2001013928A1 (fr) Procedes de pasteurisation d'une substance immune contenant un facteur anti-inflammatoire et son utilisation
TWI620509B (zh) 飲料之用途及其製造方法
RU2039445C1 (ru) Способ получения ферментированного продукта из пахты
JPWO2001013928A1 (ja) 抗炎症因子含有免疫性物質の殺菌方法及びその利用
EP0934073B1 (fr) Composition pharmaceutique, comprenant des proteines de complement, destinee au traitement des infections a helicobacter, et procede de preparation de la composition
US20070212367A1 (en) Novel immunologically active peptide fragments of a proline-rich polypeptide isolated from colostral mammalian fluids for treatment of viral and non-viral diseases or diseased conditions
JP4408764B2 (ja) ＩｇＧ抗体含有明らか食品の製造方法
JP2000159687A (ja) 非有益腸内微生物定着阻止剤
JP2001502309A (ja) 溶血性尿毒性症候群を予防するための経口投与薬剤を製造するために免疫グロブリン製剤を使用する方法
WO2006093013A1 (fr) Agent reduisant le cholesterol serique, son procede de production, et composition alimentaire et pharmaceutique agissant sur la reduction du cholesterol serique
JP2006136259A (ja) 抗体の残存率を高めた乳清タンパクの製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase